Covaxin - AAP 5370537724001
Indian pharmaceutical firm Bharat Biotech says an interim analysis of stage-three trials of its COVID-19 vaccine have shown that it has 81-per-cent efficacy in preventing the disease.
The Hyderabad-based pharmaceutical s jab BBV152, or Covaxin, has been indigenously developed with the support of the state-run Indian Council of Medical Research (ICMR).
Covaxin is one of the two vaccines currently being used to inoculate Indians.
The other is AstraZeneca and Oxford University s vaccine, produced locally by the Serum Institute of India under the name Covishield.
Both recieved emergency authorisation from India s drugs controller in January.
Covaxin s authorisation came in for criticism, as unlike Covishield there was no interim data from stage-three clinical trials on humans at the time.